



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	_
09/701,080	02/27/2001	Mark J. O'Connor	117-328	5965	
7	7590 04/16/2002				
Nixon & Vanderhye 8th Floor 1100 North Glebe Road			EXAMINER		
			SALIMI, ALI REZA		
Arlington, VA 22201-4714			ART UNIT	PAPER NUMBER	_
			1648	11	_
			DATE MAILED: 04/16/2002	11	

Please find below and/or attached an Office communication concerning this application or proceeding.

Application No.

09/701,080

Applicant(s)

Examiner

O'Connor et al

Office Action Summary

A. R. SALMI

Art Unit 1648



The MAILIN	G DATE of this communication appears	on the cover sheet with the correspondence address
Period for Reply		
	TUTORY PERIOD FOR REPLY IS SET E OF THIS COMMUNICATION.	T TO EXPIRE One MONTH(S) FROM
- Extensions of time ma	y be available under the provisions of 37 C THS from the mailing date of this communic	CFR 1.136 (a). In no event, however, may a reply be timely filed
- If the period for reply	specified above is less than thirty (30) days	s, a reply within the statutory minimum of thirty (30) days will
		period will apply and will expire SIX (6) MONTHS from the mailing date of this
- Any reply received by		y statute, cause the application to become ABANDONED (35 U.S.C. § 133). e mailing date of this communication, even if timely filed, may reduce any
Status		
1) Responsive to	communication(s) filed on 2/27/01;	11/24/00 .
2a) $\square$ This action is	FINAL. 2b) This ac	tion is non-final.
		except for formal matters, prosecution as to the merits is arte Quayle, 1935 C.D. 11; 453 O.G. 213.
Disposition of Claims		
4) 💢 Claim(s) <u>36-5</u>	5	is/are pending in the application.
4a) Of the abov	re, claim(s)	is/are withdrawn from consideration.
5) 🗆 Claim(s)		is/are allowed.
_		is/are rejected.
7) 🗌 Claim(s)		is/are objected to.
8) 💢 Claims <u>36-55</u>		are subject to restriction and/or election requirement.
Application Papers		
9) The specificat	ion is objected to by the Examiner.	
10) The drawing(s	s) filed onis/are	e objected to by the Examiner.
11) The proposed	drawing correction filed on	is: a) $\square$ approved b) $\square$ disapproved.
12) The oath or de	eclaration is objected to by the Exam	iner.
Priority under 35 U.S.	C. § 119	
13) Acknowledger	ment is made of a claim for foreign p	priority under 35 U.S.C. § 119(a)-(d).
a) 🗌 All b) 🔲 S	Some* c)□ None of:	•
<del></del>	copies of the priority documents have	
	copies of the priority documents have	
a	f the certified copies of the priority d pplication from the International Bure I detailed Office action for a list of th	
	ment is made of a claim for domestic	
Attachment(s)		
15) Notice of References Cit	ted (PTO-892)	18) Interview Summery (PTO-413) Paper No(s).
	s Patent Drawing Review (PTO-948)	19) Notice of Informal Patent Application (PTO-152)
17) Information Disclosure S	Statement(s) (PTO-1449) Paper No(s).	20) Other:

Art Unit: 1648

## **DETAILED ACTION**

## Response to Amendment

The receipt of preliminary amendment A, and B of 2/27/01, are acknowledged. Claims 1-11, 27-35 have been canceled. Claims 36-55 have been added and are pending.

## Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in response to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 36-44, and 52-55, drawn to method of determining compound capable of disrupting interaction between two polypeptide (Please note if this group is selected further select one sequence in addition to SEQ ID NO: 1, to be examined on the merits, and amend the claims accordingly, see below for explanation)

Group II, claim(s) 45-47, drawn to a method of identifying a compound which interacts with a polypeptide. (Please note if this group is selected further select one sequence in addition to SEQ ID NO: 1, to be examined on the merits, and amend the claims accordingly, see below for explanation)

Art Unit: 1648

Group III, claim(s) 48, drawn to a purified polypeptide. (Please note if this group is selected further select one sequence in addition to SEQ ID NO: 1, to be examined on the merits, and amend the claims accordingly, see below for explanation)

Page 3

Group IV, claim(s) 49-51, drawn to polynucleotide molecule. (Please note if this group is selected further select one sequence in addition to SEQ ID NO: 1, to be examined on the merits, and amend the claims accordingly, see below for explanation)

The inventions listed as Groups I-IV do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: The invention of Group I is known in the prior art as evidence by Yang et al (1996), and Nakatani et al (WO 98/03652, see the claims). The cited evidence prove that the technical feature of Group I does not make a contribution over the prior art. Thus, the claims are not so linked by a special technical feature within the meaning of PCT Rule 13.2 as such the restriction is proper.

Upon election of Group I, II, III, or IV Applicants are additionally required to elect a single Sequence identified by a specific sequence identification number, in addition to SEQ ID NO: 1, as indicated above as they apply to group(s). The recited sequences have different structures one from other and the search for the sequences would be unduly burdensome. This

Art Unit: 1648

requirement is not to be construed as a requirement for an election of species, since each of the sequence(s) recited in alternative form is not a member of a single genus of invention, but constitutes an <u>independent and patentably distinct invention</u>.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

## Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to A. R. Salimi whose telephone number is (703) 305-7136. The examiner can normally be reached on Monday-Friday from 9:00 Am to 6:00 Pm.

Page 4

Page 5

Art Unit: 1648

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James Housel, can be reached on (703) 308-4027. The fax phone number for this Group is (703) 305-3014, or (703) 308-4242.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

A. R. Salimi

4/10/2002

A Sold Strategy